- Trials with a EudraCT protocol (39)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
39 result(s) found for: Chimeric Gene.
Displaying page 1 of 2.
EudraCT Number: 2015-005010-30 | Sponsor Protocol Number: KTE-C19-104 | Start Date*: 2017-09-27 | |||||||||||
Sponsor Name:Kite Pharma, Inc. | |||||||||||||
Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4) | |||||||||||||
Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DE (Ongoing) FR (Ongoing) CZ (Ongoing) SE (Restarted) BE (Ongoing) PL (Temporarily Halted) IT (Restarted) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001730-34 | Sponsor Protocol Number: TX200-KT02 | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:Sangamo Therapeutics France SAS | |||||||||||||
Full Title: A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Ce... | |||||||||||||
Medical condition: Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 po... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) DE (Completed) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005843-21 | Sponsor Protocol Number: KT-US-982-5968 | Start Date*: 2022-02-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:KITE PHARMA INC. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Long-term Follow-up Study for Participants of Kite Sponsored Interventional Studies Treated With Gene-Modified Cells | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: B-cell malignancies and Acute Myeloid Leukemia | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) DE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003047-19 | Sponsor Protocol Number: Sym004-09 | Start Date*: 2016-03-02 | |||||||||||
Sponsor Name:Symphogen A/S | |||||||||||||
Full Title: An Open label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination with FOLFIRI in Patients with Metastatic Colorectal Cancer Progressing after First-Line Therapy | |||||||||||||
Medical condition: Patients with locally advanced or metastatic CRC, wild type KRAS/NRAS (exon 2, 3, 4) will be enrolled. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004590-51 | Sponsor Protocol Number: 233AS303 | Start Date*: 2021-09-15 | |||||||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed... | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) BE (Completed) IT (Ongoing) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017384-42 | Sponsor Protocol Number: 838 | Start Date*: 2010-05-17 | |||||||||||
Sponsor Name:Academisch ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Safety and efficacy of the addition of simvastatin to cetuximab in k-ras mutant advanced or metastatic colorectal cancer patients. A single-arm, multicenter, phase II study using a Simon two stage ... | |||||||||||||
Medical condition: k-ras mutant advanced or metastatic colorectal cancer failing prior 5-FU, oxaliplatin, and irinotecan containing regimens. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004808-60 | Sponsor Protocol Number: HD-CAR-1/V04 | Start Date*: 2018-04-12 | ||||||||||||||||
Sponsor Name:University Hospital Heidelberg | ||||||||||||||||||
Full Title: Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector - A unicenter Phase I /II clinical trial | ||||||||||||||||||
Medical condition: Relapsed and/or refractory CD19+ leukemia and lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000296-24 | Sponsor Protocol Number: CL1-68587-002 | Start Date*: 2017-10-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | |||||||||||||
Full Title: Phase I, open label, dose-escalation study to evaluate the safety, expansion and persistence of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen recepto... | |||||||||||||
Medical condition: Patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005009-35 | Sponsor Protocol Number: KTE-C19-103 | Start Date*: 2018-09-25 | |||||||||||
Sponsor Name:Kite Pharma Inc. | |||||||||||||
Full Title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) | |||||||||||||
Medical condition: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001465-24 | Sponsor Protocol Number: GC-LTFU-001 | Start Date*: 2018-02-26 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. | |||||||||||||
Medical condition: Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) AT (Trial now transitioned) FI (Ongoing) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001023-38 | Sponsor Protocol Number: bb2121-MM-003 | Start Date*: 2019-05-13 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (... | ||||||||||||||||||
Medical condition: Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of com... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) SE (Completed) DE (Ongoing) BE (Ongoing) NO (Ongoing) IT (Ongoing) ES (Ongoing) NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002245-29 | Sponsor Protocol Number: BB2121-MM-001 | Start Date*: 2018-10-02 | ||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||
Full Title: A phase 2, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma | ||||||||||||||||||
Medical condition: Relapsed and Refractory Multiple Myeloma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000297-38 | Sponsor Protocol Number: CL1-68587-003 | Start Date*: 2016-06-22 | ||||||||||||||||
Sponsor Name:Institut de Recherches Internationales Servier (I.R.I.S) | ||||||||||||||||||
Full Title: Long-term follow-up study of patients who have previously been exposed to UCART19 / ALLO-501 (allogeneic engineered T-cells expressing a lentiviral-based anti-CD19 chimeric antigen receptor) | ||||||||||||||||||
Medical condition: Advanced lymphoid malignancies | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) FR (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022422-32 | Sponsor Protocol Number: RHMCAN0749 | Start Date*: 2010-12-20 |
Sponsor Name:University Hospital Southampton NHS Foundation Trust | ||
Full Title: A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib | ||
Medical condition: Diffuse Large B-cell Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000900-38 | Sponsor Protocol Number: FT01CARCIK | Start Date*: 2017-08-16 | |||||||||||
Sponsor Name:FONDAZIONE TETTAMANTI M.DE MARCHI ONLUS | |||||||||||||
Full Title: Open label, single arm, multicenter, dose escalation Phase I-IIa, trial to determine the safety of Allogeneic (donor derived) Cytokine Induced Killer (CIK) cells transduced with a transposon CD19 C... | |||||||||||||
Medical condition: Relapsed or Refractory B cell Acute Lymphoblastic Leukemia after Haematopoietic Stem Cell Transplantation | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000121-32 | Sponsor Protocol Number: 68284528MMY2001 | Start Date*: 2019-09-03 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma | |||||||||||||
Medical condition: Relapsed or Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001413-16 | Sponsor Protocol Number: 68284528MMY3002 | Start Date*: 2020-05-15 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, ... | |||||||||||||
Medical condition: Relapsed and lenalidomide-refractory multiple myeloma (MM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) NL (Ongoing) PL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004729-55 | Sponsor Protocol Number: GD2CAR02 | Start Date*: 2023-07-14 | |||||||||||
Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA | |||||||||||||
Full Title: Phase I study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric and young adult patients affected by relapsed/refractory central nervous system tumors | |||||||||||||
Medical condition: Relapsed/refractory malignant central nervous system tumors | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002713-34 | Sponsor Protocol Number: ITCC-098 | Start Date*: 2021-12-30 |
Sponsor Name:Princess Maxima Center for Pediatric Oncology in The Netherlands | ||
Full Title: A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors | ||
Medical condition: relapsed/refractory ALK rearranged** or ALK mutated tumors, including relapsed/refractory ALK+ALCL and ALK+IMT. | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) ES (Ongoing) DK (Ongoing) SE (Ongoing) IT (Ongoing) DE (Ongoing) NO (Ongoing) BE (Ongoing) FI (Ongoing) PL (Ongoing) AT (Ongoing) CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005008-27 | Sponsor Protocol Number: KTE-C19-102 | Start Date*: 2018-08-16 | ||||||||||||||||
Sponsor Name:Kite Pharma, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2) | ||||||||||||||||||
Medical condition: Relapsed/Refractory Mantle Cell Lymphoma (MCL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) FR (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.